RxDoctor Payments Data

Ankit Rathod, MD

Nuclear Cardiology · Fresno, CANPI 1073751962

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,488 of the $2,156 with a category attached, or 69.0%. Siemens Medical Solutions USA, Inc. accounts for 81.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,862 and has fallen 89.7% since, to $191 in 2024.

$2,156in general payments, 2019–2025

Across 26 payments — averaging $82.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$2K
  • Amgen$165
  • United Therapeutics Corporation$98
  • E.r. Squibb & Sons, L.L.C.$42
  • Actelion Pharmaceuticals US, Inc.$35
  • Lexicon Pharmaceuticals, Inc.$21
  • plus $30 from 2 others

What the payments were for

  • Travel & lodging$1,48869%
  • Food & beverage$66831%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$253,675
Medicare patients
1,298
Services billed
3,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan42$55,721
EliquisApixaban36$43,558
JardianceEmpagliflozin25$26,087
Metoprolol Succinate186$3,913
Atorvastatin Calcium229$3,363
Rosuvastatin Calcium85$1,624
Carvedilol107$1,027
Isosorbide Mononitrate ErIsosorbide Mononitrate52$970
Ezetimibe25$965
Losartan Potassium83$771
ClopidogrelClopidogrel Bisulfate43$730
Lisinopril56$636
Pravastatin Sodium35$585
Amlodipine Besylate78$579
Bumetanide15$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$14$55,72142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →